- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02665689
Influence of Diabetes Control on Treatment of Diabetic Macular Edema With Ranibizumab (DORO)
Study Overview
Status
Intervention / Treatment
Detailed Description
Patients with diabetic macular edema (DME) will be treated with intravitreal ranibizumab injections and the effect of optimal control of internal factors (eg. glycemia, blood pressure etc) on final functional (best corrected visual acuity-CBVA) and morphological (central retinal thickness-CRT) will be investigated. Patients will be randomized into two groups: Group with intensified diabetic control will be follow and investigated monthly at department of diabetology, endocrinology and nutritional medicine (Campus Benjamin Franklin) in Berlin with aim to reach the optimal glycemic control defined as HbA1c < 6,5%. Further, triglycerides values < 140 mg/dl and blood pressure < 140/90 mmHg will be pursued. Second group of patients will be followed by their general practitioner and in the study center only blood samples will be taken quarterly without active medical intervention.
BCVA, CRT and the number of required ranibizumab injections will we evaluated and compared between both study groups.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 12203
- Department of Ophthalmology, Charite, Berlin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with diabetic macular edema relevant to visual acuity
- OCT central retinal thickness ≥ 250µm
- HbA1c > 6,5% at initial visit
- BCVA ≤0.8 and ≥0.05
- Age ≥18 years
- Written patient informed consent given
Exclusion Criteria:
- Previous treatment with intravitreal drugs in last 6 months
- Vitreous hemorrhage as a consequence of proliferative retinopathy
- Pregnancy
- Blood pressure of ≥ 180/100 (or uncontrolled pressures under pharmacological therapy)
- Chronic systemic or ocular inflammatory/autoimmune diseases (e.g. inflammatory bowel disease, Addison´s disease, Cushing Syndrome, Uveitis)
- Systemic cortisone or anti-VEGF therapy
- Acute systemic or ocular infectious diseases
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Regular Glycemic Control
Diabetic macular edema will be treated with 3 monthly ranibizumab (0,5mg) injections followed by PRN regimen.
Patients randomized into this group will be controlled by their general practitioner or private diabetologist (usual care).
The glycemic control (blood measurements of HbA1c) will be performed at trial site (Department of diabetology, endocrinology and nutritional medicine) every 3 months.
The site will not influence or change the diabetes medication given by general physician and serves as an observer only to monitor the diabetic control.
|
Ranibizumab injections will be given for diabetic macular edema.
In the experimental arm insulin injections and antihypertensiva will be applied.
|
Experimental: Intensified Glycemic Control
Diabetic macular edema will be treated with 3 monthly ranibizumab (0,5mg) injections followed by PRN regimen. Patients randomized into this group will be controlled at the trial site (Department of diabetology, endocrinology and nutritional medicine) during first year monthly, in the second study year every 3 months. The individual HbA1c will be targeted according to the general status reflecting other risk factors for the vasculopathy (e.g. BMI, smoking, blood pressure, lipid status). All effort will be done to reach the target blood pressure ≤ 140/90 mmHg and blood triglyceride level < 140 mg/dl: Further the patients will be educated to improve their eating habits in regard to reduce the carbohydrate intake. |
Ranibizumab injections will be given for diabetic macular edema.
In the experimental arm insulin injections and antihypertensiva will be applied.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference of Best Corrected Visual Acuity Measured in ETDRS Letters Score Between Month 12 Baseline Visit
Time Frame: Baseline to 12 months
|
Measured by the difference in ETDRS letters score between month 12 and baseline according to internal guideline of Charité department of ophthalmology.
|
Baseline to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Treatments With Ranibizumab up to 6, 12, 18 and 24 Months of Treatment
Time Frame: Baseline to 12 months
|
For the number of treatments at 6, 12, 18 and 24 months, an ANOVA without any covariates was planned to be applied at each endpoint 6, 12, 18 and 24 months. As the time point 12 months for the evaluation of this secondary endpoint was reached only for patients of study arm B, a comparison of both study arms was not possible and thus statistical analysis of the endpoint was waived completely. None of the patients reached time points beyond month 12. Results are only shown descriptively. Ranibizumab injections were summed up per study arm as well as cumulative at each time point. |
Baseline to 12 months
|
Difference of Best Corrected Visual Acuity Measured in ETDRS Letters Score Between Month 6, 12, 24 and Baseline Visit
Time Frame: Baseline to 12 months
|
As the time point 12 months for the evaluation of this secondary endpoint was reached only for patients of study arm B, a comparison of both study arms was not possible and thus analysis of the endpoint was waived completely. Time point 24 months was reached by none of the patients due to trial discontinuation. Results are only shown descriptively. Best-corrected visual acuity (BCVA) score is shown as change in ETDRS letters score at the distinct time point compared to baseline. Higher scores mean a better outcome. |
Baseline to 12 months
|
Macular Thickness Change at 6, 12, 18 and 24 Months Compared to Baseline
Time Frame: Baseline to 12 months
|
As the time point 12 months for the evaluation of this secondary endpoint was reached only for patients of study arm B, a comparison of both study arms was not possible and thus analysis of the endpoint was waived completely. None of the patients reached time points beyond month 12 due to trial discontinuation. Results are only shown descriptively. Macular thickness (study eye) is shown as change in thickness [µm] compared to individual baseline value. A reduction in thickness means improvement. |
Baseline to 12 months
|
Time to Reach Target HbA1c
Time Frame: 24 months
|
24 months
|
|
Number of Panretinal Laser Photocoagulation (PRP) Treatments Necessary for Neovascular Complications
Time Frame: Baseline to 12 months
|
Need for PRP is up to the investigator's decision. Assessment was done on every visit. Intended time frame was baseline to 24 months. None of the patients reached time points beyond month 12 due to study discontinuation. Unit of measure is any separate investigator's decision to perform panretinal laser photocoagulation (PRP) for neovascular complications. Each PRP is counted separately. |
Baseline to 12 months
|
Number of Participants With Retinal Detachment, Central Retinal Artery Occlusion, or Endophthalmitis and/or Ocular Adverse Events That Are Related to Treatment
Time Frame: Baseline to 12 months
|
All ocular adverse events presented from baseline to 24 months will be documented.
|
Baseline to 12 months
|
Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment
Time Frame: Baseline to 12 months
|
All adverse events were documented. Causal relationship to study treatment was assessed by the investigators. Intended time frame was baseline to 24 months. None of the patients reached time points beyond 12 months due to study discontinuation. |
Baseline to 12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DORO001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Macular Edema, Cystoid
-
Federico II UniversityCompletedPseudophakic Cystoid Macular Edema
-
Quan Dong NguyenOculis; Global Ophthalmic Research Center (GORC)RecruitingUveitis Related Cystoid Macular Edema | Cystoid Macular Edema, PostoperativeUnited States
-
Vance Thompson Vision - MTUnknownPatient Preference | Post-Operative Inflammation | Patient Outcomes | Grade of Post-Operative Cystoid Macular Edema | Rate of Post-Operative Cystoid Macular EdemaUnited States
-
Postgraduate Institute of Medical Education and...CompletedDiabetic Macular Edema | Cataract | Vision Disorders | Macular Edema, Cystoid | Cystoid Macular Edema Following Cataract SurgeryIndia
-
Asociación para Evitar la Ceguera en MéxicoUnknownCystoid Macular EdemaMexico
-
California Retina ConsultantsRegeneron PharmaceuticalsCompletedDiabetic Macular Edema | Cystoid Macular EdemaUnited States
-
Dongyang People's HospitalRecruiting
-
University of MiamiGenentech, Inc.CompletedUveitic Cystoid Macular EdemaUnited States
-
National Eye Institute (NEI)CompletedMacular Edema, Cystoid
-
Massachusetts Eye and Ear InfirmaryRecruitingCystoid Macular EdemaUnited States
Clinical Trials on ranibizumab
-
University of Campania "Luigi Vanvitelli"Completed
-
University of Illinois at ChicagoGenentech, Inc.WithdrawnGlaucoma | Neovascular Glaucoma | New Onset Glaucoma | New Onset Neovascular Glaucoma
-
Especialistas en Retina Medica y Quirurgica Grupo...Centro de Retina Medica y Quirurgica S.C.CompletedDiabetic Macular EdemaArgentina, Mexico
-
Hanscom, Thomas, M.D.Genentech, Inc.CompletedCentral Retinal Vein Occlusion | Macular Edema | Branch Retinal Vein OcclusionUnited States
-
Lupin Ltd.RecruitingNeovascular Age-related Macular DegenerationIndia
-
Hawaii Pacific HealthGenentech, Inc.CompletedPolypoidal Choroidal Vasculopathy | PCVUnited States
-
New England Retina AssociatesGenentech, Inc.CompletedChoroidal MelanomaUnited States
-
Samsung Bioepis Co., Ltd.CompletedAge-Related Macular DegenerationKorea, Republic of, United States, India, Germany, Hungary, United Kingdom, Czechia, Poland, Russian Federation
-
Peter A Campochiaro, MDGenentech, Inc.CompletedRetinal Vein OcclusionUnited States
-
Instituto de Olhos de GoianiaCompleted